PUB-009 / v2.0
Assessing a case as a research opportunity
This note turns a professional observation into a testable question. Savings, adherence and efficacy claims need corresponding evidence.
From recurring need to research question
Repeated requests are a signal to investigate, not proof of market size or efficacy. Record a denominator, available solutions and why they do not meet the need. Define dosage form, concentration, device, duration and critical quality attributes. Then assess feasibility, scaling, testing and the appropriate regulatory route.
What each source supports
An official monograph can establish formula and tests without publishing a complete stability study. A product label can support active-drug warnings without covering the compounded vehicle. Assess authority, exact edition and claim applicability. References identify their actual scope of support rather than serving as a decorative list.
Scope and professional responsibility
Article 3 of Directive 2001/83/EC provides specific scope exclusions: pharmacy preparation against a prescription for an individual patient and, separately, pharmacopoeial preparation supplied directly to that pharmacy’s patients. This is not a blanket exemption for every activity called compounding and does not remove national quality or operational requirements. Industrial product development and supply require a separate regulatory assessment.
Data and traceability
Using technical experience does not require publishing identifiable patient information. Public documents describe questions and technical findings without personal details. Full order/material/batch/recipient linkage remains in the pharmacy’s protected system. Research use of data requires appropriate separate governance.
Sources and references
- PIC/S — Guide to Good Practices for the Preparation of Medicinal Products in Healthcare EstablishmentsPE 010-4, 1 March 2014Chapters 1–9; Annex 2 (nonsterile liquids, creams, ointments)Professional quality-system framework; not automatic national legal adoption or certification2026-09-12
- European Parliament and Council — Directive 2001/83/ECConsolidated text displayed as current on 2026-09-12Articles 2, 3(1)–(2), 6; consolidated 1 January 2025Specific EU scope exclusions; national pharmacy conditions still require verification2026-09-12
- NAPRA — Model Standards for Pharmacy Compounding of Non-sterile PreparationsMarch 2018, clarification January 2022Sections 4–9Risk, personnel, facilities and QA; its historical BUD table is not used for current USP defaults2026-09-12